Shots:

• The P-II (GALAXI 1) trial evaluates Tremfya vs Stelara in patients with active CD with inadequate response/intolerance to conventional therapies & biologics
• The results showed that patients treated with 200mg IV/100mg SC achieved clinical remission/corticosteroid-free clinical remission/PROs (63.9%/59%/57.4%), (73%/71.4%/69.8%) with 600mg IV & 200mg SC, 57.4%/55.7%/50.8% with 1200 mg IV/200 mg SC over 58.7%/58.7%/ 46%, respectively
• Additionally, all dose groups @ 48wk. had comparable safety data, consistent with the known safety profile for Tremfya. In dose group of 200mg IV/100mg SC, 600mg IV/200mg SC, 1200mg IV/200mg SC & Stelara, AEs were reported in 71.2%, 80.8%, 69.9% & 84.5%, respectively

 Ref: PR Newswire | Image: Medical Dialogues